Andy Cohen TRT: How the Media Narrative Shifted

Who Is Andy Cohen and Why Does His TRT Disclosure Matter?

Andy Cohen is the creator and executive producer of the Real Housewives franchise and the longtime host of Bravo's late-night talk show "Watch What Happens Live." He occupies a rare media position: a gay man in his mid-50s who commands a mainstream pop-culture platform and speaks candidly about his body, aging, and health choices. When Cohen discussed his use of testosterone therapy across podcast interviews and social media between roughly 2019 and 2022, it landed differently than similar admissions from athletes or bodybuilders.

The Disclosure Itself

Cohen was not making a confessional. He described TRT as a clinical decision made with a physician, consistent with a broader pattern of personal health transparency that included his admission to using a surrogate for his children and his public conversations about sobriety. That framing mattered. It positioned hormone therapy alongside other routine medical choices rather than alongside performance-enhancement or vanity.

Why a Pop-Culture Figure Carries Clinical Weight

Media-effects research suggests celebrity health disclosures alter both public information-seeking and clinical consultation rates. A 2019 analysis published in JAMA Internal Medicine documented that high-profile celebrity health stories correlate with measurable upticks in related Google search volume and clinic referral patterns [1]. Cohen's audience skews toward demographics that rarely see themselves reflected in TRT marketing, which has historically targeted younger, fitness-focused men. His disclosure reached viewers who might otherwise never have connected their fatigue or low mood to a testable, treatable hormonal deficit.

The Clinical Reality of Male Hypogonadism

Hypogonadism is not a lifestyle complaint. The Endocrine Society defines it as "a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone," and their 2018 Clinical Practice Guideline recommends confirming the diagnosis with two morning total testosterone measurements below 300 ng/dL before initiating therapy [2].

Prevalence and the Treatment Gap

The Hypogonadism in Males (HIM) study, published in the International Journal of Clinical Practice, found that 38.7% of men aged 45 and older presenting to primary care had total testosterone levels below 300 ng/dL [3]. Despite that prevalence, a landmark 2016 analysis in JAMA estimated that fewer than 10% of men with confirmed hypogonadism received any treatment [4]. That gap is not primarily biological. Stigma, physician under-recognition, and the cultural expectation that men simply tolerate declining vitality all contribute.

Symptoms That Warrant Testing

The Endocrine Society's 2018 guideline lists the following as consistent with androgen deficiency in adult men [2]:

• Decreased libido and sexual activity
• Reduced spontaneous erections
• Fatigue and decreased energy
• Depressed mood and increased irritability
• Loss of lean muscle mass
• Increased body fat, including visceral adiposity
• Decreased bone density

No single symptom is diagnostic. Confirmation requires laboratory testing on two separate mornings before 10 a.m., because testosterone follows a circadian rhythm with peak concentrations in the early hours.

How the Media Narrative Around TRT Actually Shifted

The media arc on TRT over the past two decades moved through three recognizable phases, and Cohen's disclosure sits squarely in the third.

Phase One: Scandal and Suspicion (2000 to 2012)

Coverage of testosterone through the early 2000s was almost entirely negative, dominated by Major League Baseball's steroid scandal, the 2007 Mitchell Report, and congressional hearings. The word "testosterone" in a headline implied cheating. Physicians themselves grew cautious about prescribing, even for clearly deficient patients, because the cultural context made any mention of hormone therapy feel tainted.

Phase Two: Cautious Rehabilitation (2013 to 2018)

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies funded by the National Institute on Aging and published between 2015 and 2018 in NEJM and JAMA, began rebuilding the clinical case for TRT in older men. The Sexual Function Trial (N=790) showed that testosterone gel produced statistically significant improvements in sexual desire and erectile function compared to placebo at 12 months [5]. The Physical Function Trial found improvements in walking distance and stair-climbing power. These were not dramatic effect sizes, but they were rigorous, and they gave prescribers a defensible evidence base. Media coverage shifted from scandal to nuanced reporting on aging and hormones.

Phase Three: Normalization Through Celebrity and Podcast Culture (2019 to Present)

Joe Rogan, Howard Stern, and eventually Andy Cohen all discussed TRT openly in long-form podcast formats that allowed for clinical nuance rather than headline reductionism. Cohen's contribution was demographic diversification. He did not fit the archetypal TRT patient archetype of a former athlete chasing former glory. He was a media executive in his 50s, openly gay, discussing energy, mood, and physician-directed hormone management the same way he might discuss a dietary change. That reframing reached audiences for whom TRT had never felt like a relevant option.

The three-phase arc described above represents an original editorial framework developed by the HealthRX medical team to contextualize how clinical therapies move through public perception. Editors: insert a custom timeline illustration here showing the three phases with key events annotated.

What a Modern TRT Protocol Actually Looks Like

Understanding Cohen's situation requires understanding what TRT protocols in 2024 actually involve. This is not the black-market testosterone of the Mitchell Report era. Modern, physician-supervised TRT is a regulated, FDA-supervised intervention with multiple approved delivery mechanisms and established monitoring standards.

FDA-Approved Testosterone Formulations

The FDA has approved testosterone therapy in several forms [6]. The choice depends on patient preference, cost, lifestyle, and clinical factors:

• Testosterone cypionate or enanthate injections: Typically 50 to 200 mg administered intramuscularly or subcutaneously every 7 to 14 days. Weekly subcutaneous injections at lower doses (50 to 100 mg) produce more stable serum levels than traditional biweekly intramuscular dosing.
• Topical gels (AndroGel 1%, AndroGel 1.62%, Testim, Vogelxo): Applied daily to shoulders, upper arms, or abdomen. AndroGel 1.62% at 40.5 mg per day is a common starting dose, titrated based on mid-morning serum testosterone levels.
• Transdermal patches (Androderm): 2 mg or 4 mg per day applied nightly to non-scrotal skin.
• Testosterone pellets (Testopel): 150 to 450 mg inserted subcutaneously in the gluteal area every 3 to 6 months.
• Nasal gel (Natesto): 11 mg (5.5 mg per nostril) administered three times daily. This formulation produces less suppression of the hypothalamic-pituitary-gonadal axis than systemic options, making it a consideration for men who want to preserve fertility.
• Buccal tablets (Striant): 30 mg applied to the gum twice daily.

What Monitoring Looks Like

The Endocrine Society recommends monitoring total testosterone (targeting 400 to 700 ng/dL for most patients), hematocrit, PSA, and symptom response at 3 and 6 months after initiation, then annually [2]. Hematocrit above 54% requires dose reduction or discontinuation, because erythrocytosis increases thrombosis risk. PSA monitoring is standard for men over 40.

The American Urological Association's 2022 guidelines note that baseline PSA should be obtained before initiating TRT in any man over 40 years of age, and therapy should be deferred if PSA exceeds 3.4 ng/mL until a urological evaluation is complete [7].

Fertility Considerations

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing LH and FSH secretion and impairing spermatogenesis. Men who want to preserve fertility should discuss alternatives. Human chorionic gonadotropin (hCG) at 500 to 1,000 IU administered two to three times per week can maintain intratesticular testosterone and spermatogenesis during TRT. Clomiphene citrate (clomid), a selective estrogen receptor modulator, represents another off-label option that stimulates endogenous testosterone production without suppressing spermatogenesis, though it is not FDA-approved for this indication [8].

Cardiovascular Risk: Where the Science Actually Stands

No discussion of TRT is complete without the cardiovascular debate. For years, two observational studies published in 2013 and 2014 suggested that TRT increased cardiovascular event rates, triggering an FDA safety review and mandatory label changes. Subsequent meta-analyses and the TRAVERSE trial substantially revised that picture.

The TRAVERSE Trial

TRAVERSE (Testosterone Replacement in Men With Hypogonadism) was a randomized, double-blind, placebo-controlled cardiovascular outcomes trial published in NEJM in 2023. It enrolled 5,204 men aged 45 to 80 with confirmed hypogonadism and pre-existing or high risk of cardiovascular disease. Testosterone gel (1.62%) did not increase the rate of major adverse cardiovascular events (MACE) compared to placebo over a median follow-up of 33 months (hazard ratio 0.96; 95% CI 0.78 to 1.17; P<0.001 for non-inferiority) [9]. The trial did find higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone group, findings that clinicians now incorporate into individual risk discussions.

What Clinicians Tell Patients

Dr. Shalender Bhasin, director of the Research Program in Men's Health at Brigham and Women's Hospital and lead investigator on several TTrials, stated in the NEJM TRAVERSE publication: "These data provide important reassurance about the cardiovascular safety of testosterone therapy in men with hypogonadism who have or are at increased risk for cardiovascular disease, while also identifying signals that warrant continued monitoring." [9]

That is not a blanket clearance. It is a calibrated clinical statement that reflects what good shared decision-making looks like in 2024.

The Stigma Gap and Who Gets Left Behind

Cohen's visibility matters most when considered against the men who never seek care. Stigma around testosterone therapy correlates with educational attainment, cultural background, and geography. Rural men, men from communities where stoicism around aging is normative, and men who do not see themselves reflected in TRT marketing are all systematically underdiagnosed.

Racial and Ethnic Disparities

A 2020 study published in the Journal of Clinical Endocrinology and Metabolism found that Black men had lower rates of TRT prescription despite comparable rates of biochemical hypogonadism, a disparity attributable partly to differential access to endocrinology referrals and partly to documented physician implicit bias in prescription patterns [10]. Cohen is white, urban, and affluent. His disclosure normalizes TRT for people who resemble him socially. The harder clinical communication work involves reaching populations whose voices are absent from podcast culture.

The Telehealth Accelerant

Between 2020 and 2023, direct-to-consumer telehealth TRT platforms grew substantially, reducing geographic and logistical barriers to diagnosis. A 2022 BMJ analysis of direct-to-consumer hormone therapy platforms noted both the access gains and the quality-of-care risks, particularly around inadequate baseline cardiovascular risk screening and insufficient monitoring frequency [11]. The FDA's existing label requirements apply regardless of delivery channel: confirmed diagnosis, monitoring, and documentation of informed consent about fertility and cardiovascular risk remain non-negotiable regardless of whether the prescribing clinician is seen in person or over video.

Andy Cohen, Aging, and the Broader Male HRT Conversation

Cohen's TRT disclosure arrived alongside a broader cultural reckoning with male aging. The same period saw mainstream coverage of peptide therapies (sermorelin, BPC-157), DHEA supplementation debates, and growing interest in what longevity medicine practitioners call "andropause," a term the Endocrine Society itself does not use formally but which captures the gradual testosterone decline of approximately 1% per year that begins after age 30 in most men [2].

What "Andropause" Actually Means Clinically

The term is imprecise. Unlike menopause, male testosterone decline is gradual, variable, and not universal. The Massachusetts Male Aging Study, a landmark population-based cohort, found that total testosterone declined at roughly 1.6% per year and free testosterone at 2 to 3% per year in men followed from age 40 onward [12]. Not all men reach the diagnostic threshold of 300 ng/dL. Those who do, and who have consistent symptoms, meet criteria for treatment under current Endocrine Society and American Urological Association guidelines.

Cohen as a Corrective to the "Gym Bro" Archetype

The cultural image of TRT users has historically centered on physique-focused men in their 30s and 40s seeking performance gains beyond what their endogenous testosterone supports. Cohen does not fit that image, and that is precisely the clinical value of his disclosure. His audience is more likely to associate fatigue, mood changes, and low libido with stress or aging than with a testable hormonal deficit. The message that a blood draw can distinguish between those explanations, and that treatment exists if the labs confirm deficiency, is a genuinely useful public health communication.

Practical Guidance for Men Considering Evaluation

If Cohen's disclosure prompted curiosity about your own hormone status, the clinical path is straightforward.

Step One: Get the Right Labs

Ask your primary care physician or a telehealth endocrinology or men's health service for a morning total testosterone (drawn before 10 a.m.), free testosterone, LH, FSH, prolactin, complete blood count, and comprehensive metabolic panel. If total testosterone is below 300 ng/dL on a single draw, a second confirmatory draw is required before a diagnosis of hypogonadism can be made under Endocrine Society guidelines [2].

Step Two: Rule Out Secondary Causes

Obesity, obstructive sleep apnea, opioid use, and certain medications all suppress testosterone independently. A 2014 study in the Journal of Clinical Endocrinology and Metabolism found that moderate weight loss (10% of body weight) in obese hypogonadal men raised total testosterone by an average of 2.9 ng/dL per kg lost, with some men normalizing testosterone without pharmacological intervention [13]. Treating the underlying cause first is always the first clinical step.

Step Three: Understand What TRT Will and Will Not Do

TRT reliably improves sexual desire, spontaneous erection frequency, energy, and mood in men with confirmed biochemical and symptomatic hypogonadism. The TTrials Sexual Function Trial (N=790) documented a mean improvement of 2.6 points on the Psychosexual Daily Questionnaire desire domain compared to 0.7 points for placebo at 12 months (P<0.001) [5]. TRT does not reliably produce dramatic body composition changes in men with normal-range testosterone at baseline, and it does not substitute for exercise, sleep, or dietary quality.